Resmed Stock Price, News & Analysis

ResMed's fifth annual Global Sleep Survey of 30,026 people across 13 markets reveals a concerning global sleep crisis. People are losing nearly three nights of restorative sleep weekly, with one-third of respondents reporting sleep difficulties three or more times per week.

Key findings show that 71% of employed respondents have called in sick due to poor sleep, with highest rates in India (94%). About 18% of couples opt for 'sleep divorce' due to snoring and restlessness. Women experience poorer sleep quality than men (3.83 vs 4.13 quality nights per week).

The survey identifies primary sleep disruptors as stress (57%), anxiety (46%), and financial pressures (31%). Despite 89% believing sleep improves their well-being, only 24% would take immediate action to address sleep issues. Notably, 22% globally choose to 'just live with' poor sleep, reaching 41% in Australia.

ResMed (NYSE: RMD) reported strong Q2 FY2025 financial results with significant growth across key metrics. Revenue increased 10% to $1.3 billion, while operating profit surged 52% to $417.2 million. The company achieved notable margin improvements, with gross margin expanding 300 basis points to 58.6%.

Key highlights include operating cash flow of $309 million and diluted earnings per share of $2.34. The company's growth was driven by increased demand for sleep health and breathing products, along with digital health solutions. During the quarter, ResMed paid $78 million in dividends and repurchased 307,000 shares for $75 million.

The board declared a quarterly cash dividend of $0.53 per share, payable on March 20, 2025, to shareholders of record as of February 13, 2025.

ResMed (NYSE: RMD, ASX: RMD) has announced plans to release its second quarter fiscal 2025 financial and operational results on Thursday, January 30, 2025, after the New York Stock Exchange market close. The company will follow the release with a management-hosted webcast to discuss the quarterly results.

ResMed (NYSE: RMD, ASX: RMD) has announced that Mick Farrell, chairman and CEO, and Dr. Carlos Nunez, chief medical officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Monday, January 13, 2025, at approximately 3:00 p.m. (Pacific Standard Time) in San Francisco, CA.

The company will provide an audio-only webcast of the presentation, which can be accessed through the investor relations section of ResMed's website. A replay of the webcast will be available for 30 days following the live presentation.

Avant Technologies has entered a joint venture with Ainnova Tech to form Ai-nova Acquisition Corp (AAC), focusing on AI-powered healthcare solutions. The partnership will commercialize Ainnova's VisionAI platform and retinal cameras in North America and Europe. VisionAI can detect diabetic retinopathy and other diseases through retinal scans with high accuracy. With the global healthcare AI market projected to reach $188 billion by 2030, this venture aims to make retinal scanning a standard in primary care. The technology addresses a critical need, as 30% of 500 million diabetics globally may develop diabetic retinopathy, while there's a shortage of ophthalmologists.

ResMed (NYSE: RMD, ASX: RMD) announced that Chairman and CEO Mick Farrell and Chief Medical Officer Dr. Carlos Nunez will participate in a fireside chat at the UBS Global Healthcare Conference. The event will take place on November 12, 2024, at 3:30 p.m. PST at the Terranea Resort Hotel in Rancho Palos Verdes, CA. A live audio-only webcast will be available on the investor relations website, with a replay accessible for 30 days following the event.

ResMed reported strong Q1 FY2025 results with 11% year-over-year revenue growth to $1.2 billion. The company achieved significant improvements in profitability with operating profit up 34% and non-GAAP operating profit increasing 27%. Gross margin improved 420 basis points to 58.6%, while operating cash flow reached $326 million. Diluted earnings per share grew to $2.11, with non-GAAP EPS at $2.20. Growth was driven by increased demand for sleep devices and masks, along with strong performance in the Residential Care Software business. The company declared a quarterly dividend of $0.53 per share.

ResMed (NYSE: RMD, ASX: RMD) has announced plans to release its financial and operational results for the first quarter of fiscal year 2025. The release is scheduled for Thursday, October 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. This announcement provides investors and analysts with a specific date to anticipate the company's quarterly performance update, which is important for assessing ResMed's financial health and market position in the medical equipment industry.

ResMed (NYSE: RMD, ASX: RMD) unveiled its 2030 Strategy at an Investor Day in New York City, aiming to drive growth, profitability, and shareholder returns. The company's ambition is to help over 500 million people achieve their full health potential by 2030. ResMed introduced an updated five-year financial outlook, expecting high-single-digit revenue growth and earnings growth higher than revenue growth.

The 2030 Strategy focuses on three pillars: growing the core sleep apnea franchise, capitalizing on opportunities in broader sleep and breathing health, and investing 7% of revenue into R&D to create an integrated digital ecosystem for home health technology. ResMed plans to leverage its leadership in connected digital health, transforming sleep health, breathing health, and health tech at home through innovative products and digital solutions.